Question 1

What is Alnylam Pharmaceuticals's deferred tax assets and other non-current assets?

Accepted Answer

Alnylam Pharmaceuticals (ALNY) reported deferred tax assets and other non-current assets of $65.13M in Q2 2026.

Question 2

How has Alnylam Pharmaceuticals's deferred tax assets and other non-current assets changed year-over-year?

Accepted Answer

Alnylam Pharmaceuticals's deferred tax assets and other non-current assets increased by 13.9% year-over-year, from $57.17M to $65.13M.

Question 3

What is the long-term trend for Alnylam Pharmaceuticals's deferred tax assets and other non-current assets?

Accepted Answer

Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's deferred tax assets and other non-current assets has grown at a 5.7% compound annual growth rate (CAGR), from $45.05M to $59.46M.

Line item	June 30, 2026	December 31, 2025
Operating lease right-of-use assets	183,359	194,916
Deferred tax assets	113,792	125,975
Restricted investments	22,171	22,170
Other assets	65,132	59,461
Total assets	$5,558,769	$4,966,331
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$108,016	$115,721

Deferred Tax Assets and Other Non-Current Assets at other companies

Other financials

Income statement

Balance sheet

Cash flow

Valuation

Profitability

Returns & leverage

Where this comes from

FAQ

Ask your AI about Alnylam Pharmaceuticals's deferred tax assets and other non-current assets.

Alnylam Pharmaceuticals ALNY Deferred Tax Assets and Other Non-Current Assets